Medical News

RSS

Feds to states: Set up health insurance pools for high-risk patients by July 1

The program, one of the highest profile provisions of the law, is designed to provide health insurance to people who have been denied coverage due to a pre-existing medical condition and have been without coverage for at least six months. It will start enrollment on July 1 and begin coverage on Aug. 1, according to guidance that Jay Angoff, director of the Department of Health and Human Service's Office of Consumer Information and Insurance Oversight, sent to state officials last week.

18 Jun 2010

Phylogeny, Neoprobe announce collaboration to develop head and neck cancer detection technology

Phylogeny, the in situ company, and Neoprobe, a diversified developer of innovative biomedical surgical oncology products, announce their collaboration to develop head and neck cancer detection technology.

18 Jun 2010

Research shows JIA patients have increased risk of cancer

Biologics-na-ve Juvenile Idiopathic Arthritis patients may have an increased risk of cancer compared with the general Swedish population, according to research presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Results of an additional study, which researched a small cohort of patients showed an increased frequency of cancer in those receiving the biologic etanercept, however, results were deemed not statistically significant by researchers.

18 Jun 2010

States want Congress to keep extra Medicaid money flowing

Illinois will face a $750 million shortfall in the fiscal year beginning in July if Congress doesn't extend increased Medicaid funding, originally part of last year's economic stimulus, Illinois Statehouse News reports. "The increased Medicaid reimbursements stand as a national issue as the recession lingers. Thirty states have crafted budgets for the fiscal year set to begin July 1 based on an extension of the increased payments, according to the National Conference of State Legislatures" (Massingale, 6/16).

18 Jun 2010

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

18 Jun 2010

$FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer$

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.

18 Jun 2010

Democrats scale back 'doc fix' in pursuit of votes to pass jobs bill, Medicaid provision may be dropped

A bill that would, among other things, extend some unemployment benefits and provide a temporary fix for Medicare physician payment rates languished in the Senate Wednesday as a procedural vote to end debate on the bill failed, 52 to 45, The Wall Street Journal reports. Eleven Democrats broke with the party to vote no.

18 Jun 2010

Study evaluates effect of Viusid on oxidative stress, cytokine parameters in patients with CHC

The pathogenesis of chronic hepatitis C is associated with severe oxidative stress and non-selective immunological disturbance that lead to necroinflammation and the progression of fibrosis. Several trials have suggested that antioxidant and immunostimulant therapies may have a beneficial effect. Two previous clinical studies have reported that the Viusid related effect on histologic features, especially fibrosis, appears to be associated with antioxidant and/or immunomodulatory properties.

18 Jun 2010

Forget play school for infants, sex school proposed in UK health guidelines

National Institute for Health and Clinical Excellence (NICE), UK has come up with its latest health proposal for the improvement of public health. The latest guidance proposal from NICE says sex education should be taught to children from the age of five. This they say is important to help them make the right decisions about delaying sexual intimacy until they are mature enough.

18 Jun 2010

Malaria rises as forests disappear: Study

Avid deforestation of the tropical forests is cited to be one of the reasons for the 50% increase in incidence of this disease in the surrounding areas according to a new research that is tracking deforestation in Brazil's Amazon.

18 Jun 2010

Baby with heart condition after surgery ‘chilled’ and cured

Four month old baby Finley Burton was taken for a routine visit to his doctor when two holes were detected in his heart. He subsequently underwent an intricate heart operation to close these holes that were making it difficult for his heart to pump out blood. Right after the operation he developed irregular, erratic heart beats that went over 200 beats per minute. This could have killed him but doctors in Britain found a miracle solution for the problem. They lowered his body temperature.

18 Jun 2010

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

Metabolon, Inc., the leader in metabolomics-based biomarker discovery and analysis, today announced the publication of research that identified a novel, early biomarker for insulin resistance and glucose intolerance in a nondiabetic population.

17 Jun 2010

FDA assigns PDUFA action date for Orexigen's Contrave NDA review

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).

17 Jun 2010

St. Jude Medical commences enrollment in LAPTOP-HF study

St. Jude Medical, Inc., a global medical device company, today announced the first enrollment in its LAPTOP-HF (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy) study. The goal of the LAPTOP-HF study is to demonstrate that the new investigational left atrial pressure (LAP) management system safely and effectively improves outcomes in patients with heart failure (HF).

17 Jun 2010

Nineteen facilities named Centers of Excellence in APBI for use of SAVI applicator

Nineteen facilities in the Mid-Atlantic region have been named Centers of Excellence in accelerated partial breast irradiation for their use of the SAVI applicator, an advanced therapy for breast cancer as part of breast conservation therapy. The SAVI applicator can provide important advantages for women with early-stage breast cancer.

17 Jun 2010

Kaplan EduNeering, DIA announce strategic alliance to create online educational offerings

Kaplan EduNeering, a leading provider of compliance and knowledge management solutions, and the Drug Information Association (DIA), a global professional member association, announced a new strategic alliance to create online educational offerings for biotechnology, pharmaceutical, academic, and regulatory professionals around the world.

17 Jun 2010

McKesson reaffirms earnings guidance for fiscal 2011

McKesson Corporation today reaffirmed its earnings guidance for the fiscal year ending March 31, 2011 and the underlying key assumptions provided in its press release of May 3, 2010. As previously stated, McKesson expects to earn between $4.72 and $4.92 per diluted share for the fiscal year ending March 31, 2011.

17 Jun 2010

China Yongxin Pharmaceuticals expands chain of drugstores to 103

China Yongxin Pharmaceuticals Inc., one of the leading health products distribution and retail sales companies in China, today announced the opening of three new chain drugstores in Changchun City. These new openings bring the Company's total number of stores to 24 in Changchun City, and 103 throughout Northeastern China, exceeding the Company's previously projected rate of growth in terms of number of locations.

17 Jun 2010

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

Results from a new survey reveal that one in three people with psoriasis do not receive proper treatment for their disease due to health insurance issues—and many won't be helped by the new health care reform law.

17 Jun 2010

First implantation of PyroTITAN Humeral Resurfacing Arthroplasty performed outside US in Australia

Ascension Orthopedics, Inc., a market leader in PyroCarbon orthopedic implants, announces the first implantation of the PyroTITAN™ Humeral Resurfacing Arthroplasty outside the United States. The PyroTITAN was implanted last month in Brisbane, Australia in a 46-year-old patient who reported "immediate pain relief" within 24 hours of surgery. The PyroTITAN Humeral Resurfacing implant is the first commercially-available shoulder arthroplasty prosthesis made of PyroCarbon in the world.

17 Jun 2010

Medical News

Feds to states: Set up health insurance pools for high-risk patients by July 1

Phylogeny, Neoprobe announce collaboration to develop head and neck cancer detection technology

Research shows JIA patients have increased risk of cancer

States want Congress to keep extra Medicaid money flowing

FDA approves Jevtana to treat men with prostate cancer

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Democrats scale back 'doc fix' in pursuit of votes to pass jobs bill, Medicaid provision may be dropped

Study evaluates effect of Viusid on oxidative stress, cytokine parameters in patients with CHC

Forget play school for infants, sex school proposed in UK health guidelines

Malaria rises as forests disappear: Study

Baby with heart condition after surgery ‘chilled’ and cured

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

FDA assigns PDUFA action date for Orexigen's Contrave NDA review

St. Jude Medical commences enrollment in LAPTOP-HF study

Nineteen facilities named Centers of Excellence in APBI for use of SAVI applicator

Kaplan EduNeering, DIA announce strategic alliance to create online educational offerings

McKesson reaffirms earnings guidance for fiscal 2011

China Yongxin Pharmaceuticals expands chain of drugstores to 103

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

First implantation of PyroTITAN Humeral Resurfacing Arthroplasty performed outside US in Australia

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News